LONDON, UNITED KINGDOM (OTCBB: NXGB), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced its intention to collaborate with Beckpharma Ltd. ("Beckpharma") - a pharmaceutical development company also involved in cancer treatments.

The two companies have formalised their desire to collaborate in a recent Letter of Intent, and are presently preparing the contractual details of their collaboration. They plan to primarily focus on the sourcing of cancer treatments, but are open to future expansion to other therapeutic areas as well.

"Beckpharma's strength lies in identifying and acquiring promising cancer treatments through the relationships it has built with academic research institutions around the world," said Konstantinos Kardiasmenos, CEO of NextGen.

"Their expertise and experience in that area would be a welcome enhancement to NextGen's current sourcing efforts."

About Beckpharma Ltd.

Beckpharma is a pharmaceutical development company whose mission is to take marketed products, as well as products at all stages of clinical development, from targeted academic institutes and other sources, add value to those products, and then commercialise them through its own resources or through industry partners in Europe, North America and other suitable territories.

About NextGen Bioscience Inc.

NextGen is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

At present, NextGen is rapidly building its portfolio of proprietary biotechnology. Its first two anti-tumor drug candidates, Prostaganin (prostate cancer) and Tetanolic (breast cancer) -- both have incredible market potential as they may ultimately eliminate the need for surgery and chemotherapy and possess no side effects. NextGen's target market -- cancer treatments -- is the largest disease market, exploding at a 20% growth rate each year. NextGen's treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). NextGen has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

For more information about NextGen Bioscience Inc., or to schedule an interview with Mr. Kardiasmenos, please contact Graham May at +44 20 7297 8186 or info@nextgenbioscience.com.

Contacts: NextGen Bioscience, Inc. Graham May +44 (0) 20 7297 8186 +44 (0) 20 7377 9454 (FAX) Email: info@nextgenbioscience.com Website: www.nextgenbioscience.com

NxGen Brands (CE) (USOTC:NXGB)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more NxGen Brands (CE) Charts.
NxGen Brands (CE) (USOTC:NXGB)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more NxGen Brands (CE) Charts.